Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19173657 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | April 2025 | August 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19173652 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | April 2025 | December 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18901009 | BONE GELATIN PROCESS | September 2024 | June 2025 | Allow | 8 | 2 | 0 | No | No |
| 18889088 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | September 2024 | May 2025 | Allow | 8 | 2 | 0 | No | No |
| 18755691 | Fusion protein and its preparation method for intermediate polypeptide of Semaglutide | June 2024 | November 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18737619 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF OXYGENATED COMPOUNDS FROM HEXOSES | June 2024 | November 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18406031 | OLFACTORY RECEPTOR INVOLVED IN THE PERCEPTION OF MUSK FRAGRANCE AND THE USE THEREOF | May 2024 | July 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18662446 | Enzyme Variants With Improved Ester Synthase Properties | May 2024 | April 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18709446 | ENGINEERED SPLIT DHFR-BASED METHODS AND SYSTEMS FOR SELECTING CELLS THAT HAVE STABLY ACQUIRED A HETEROLOGOUS POLYNUCLEOTIDE | May 2024 | February 2026 | Abandon | 21 | 1 | 1 | No | No |
| 18615341 | BOTULINUM NEUROTOXIN BIOHYBRID | March 2024 | June 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18584363 | PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18441456 | Cell-Free Protein Synthesis | February 2024 | January 2026 | Allow | 23 | 2 | 0 | Yes | No |
| 18512485 | PROMOTER FOR YEAST | November 2023 | September 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18504590 | MUTANT LYSENIN PORES | November 2023 | November 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18503341 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | November 2023 | February 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18502473 | TOXIN-DERIVED DELIVERY CONSTRUCTS | November 2023 | February 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18384018 | SINGLE ALPHA CHAIN COLLAGENS | October 2023 | November 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18486403 | COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIES | October 2023 | January 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18470985 | BIOMARKER ASSAY FOR USE IN MONITORING AUTISM | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18461658 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFORE | September 2023 | October 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18231880 | METHOD FOR SEPARATING TARGET MOLECULES OR PARTICLES FROM FIBRINOGEN-CONTAINING SAMPLES INCLUDING BLOOD COMPONENTS | August 2023 | December 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18351241 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | July 2023 | March 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18212427 | MODIFIED TRANSGLUTAMINASE | June 2023 | January 2026 | Allow | 31 | 4 | 1 | Yes | No |
| 18310317 | COORDINATED COEXPRESSION OF THROMBIN | May 2023 | October 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18123157 | ENGINEERED TISSUES HAVING STRUCTURAL COMPONENTS EMBEDDED THEREIN, AND METHODS OF MAKING AND USING | March 2023 | April 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18115724 | MANUFACTURE OF ENDOTOXIN-FREE HEMOGLOBIN-BASED DRUG SUBSTANCE AND METHOD FOR ENDOTOXIN-FREE PROTEIN PURIFICATION | February 2023 | September 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18115585 | USING BIOSOURCED RAWS FROM WASTE STREAMS TO MAKE SOURCE MATERIALS FOR OILFIELD CHEMICAL MANUFACTURE | February 2023 | May 2025 | Abandon | 27 | 4 | 0 | Yes | No |
| 18159281 | Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood | January 2023 | June 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18159283 | Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood | January 2023 | May 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18159276 | Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood | January 2023 | April 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18158680 | MICROORGANISMS AND METHODS FOR ENHANCING THE AVAILABILITY OF REDUCING EQUIVALENTS IN THE PRESENCE OF METHANOL, AND FOR PRODUCING ADIPATE, 6-AMINOCAPROATE, HEXAMETHYLENEDIAMINE OR CAPROLACTAM RELATED THERETO | January 2023 | September 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18062234 | RATIONALLY-DESIGNED SYNTHETIC PEPTIDE SHUTTLE AGENTS FOR DELIVERING POLYPEPTIDE CARGOS FROM AN EXTRACELLULAR SPACE TO THE CYTOSOL AND/OR NUCLEUS OF A TARGET EUKARYOTIC CELL, USES THEREOF, METHODS AND KITS RELATING TO SAME | December 2022 | January 2025 | Allow | 25 | 1 | 0 | No | No |
| 18056424 | OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE | November 2022 | October 2024 | Allow | 23 | 3 | 0 | No | No |
| 17925385 | FORMULATION OF PURE DIMETHOXY CURCUMIN-HUMAN SERUM ALBUMIN AND A PROCESS FOR THE PREPARATION THEREOF | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18053577 | SHORT-ACTING FACTOR VII POLYPEPTIDES | November 2022 | June 2024 | Abandon | 19 | 1 | 1 | No | No |
| 17923180 | IMMUNOTHROMBOSIS IN COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME | November 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17974381 | METHOD FOR PRODUCING NICOTINAMIDE MONONUCLEOTIDE | October 2022 | January 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 17970051 | METHOD OF PRODUCING BIOLOGICALLY ACTIVE VITAMIN K DEPENDENT PROTEINS BY RECOMBINANT METHODS | October 2022 | September 2024 | Abandon | 23 | 1 | 1 | No | No |
| 18046371 | METHOD FOR POLISHING ALBUMIN | October 2022 | November 2023 | Abandon | 13 | 0 | 1 | No | No |
| 17962153 | COMPOSITIONS, METHODS, AND APPLICATIONS OF A SYNTHETIC SURFACTANT | October 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17894593 | Methods for Extracting Proteins from a Blood-Based Material | August 2022 | September 2024 | Abandon | 24 | 6 | 0 | No | No |
| 17890416 | STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS | August 2022 | December 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17760165 | MULTIPARTITE AND CIRCULARLY PERMUTED BETA-BARREL POLYPEPTIDES AND METHODS FOR THEIR USE | August 2022 | March 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17814579 | PHARMACEUTICAL COMPOSITION FOR DIAGNOSING, PREVENTING OR TREATING LIVER CANCER USING SSU72 PROTEIN OR A POLYNUCLEOTIDE ENCODING THE SAME | July 2022 | November 2023 | Allow | 16 | 2 | 1 | Yes | No |
| 17868077 | TOXIN-DERIVED DELIVERY CONSTRUCTS | July 2022 | December 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17758825 | CELL-DERIVED VESICLES COMPRISING TARGET PROTEIN AND METHOD FOR PRODUCING SAME | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17861036 | ALCOHOL DEHYDROGENASE VARIANTS | July 2022 | April 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17854334 | CLOSTRIDIAL TOXIN - HYALURONIC ACID COMPOSITIONS | June 2022 | November 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17790406 | Strain of Beijerinckia Fluminensis and Application Thereof in Arsenic Oxidation | June 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17808450 | COMPOSITIONS AND METHODS FOR IDENTIFICATION OF MODULATORS OF RAS PROTEIN COMPLEXES | June 2022 | February 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17829032 | MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAME | May 2022 | January 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17781266 | MEDIUM COMPOSITION FOR CULTURING ANIMAL CELLS FOR PRODUCING RECOMBINANT EXTRACELLULAR MATRIX PROTEIN AND METHOD OF USING THE SAME | May 2022 | November 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17738484 | PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | May 2022 | October 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17771333 | LOW VOLUME TRANSFECTION | April 2022 | September 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17722893 | Process for Isolating a High Purity Protein Preparation from Plant Material and Products Thereof | April 2022 | October 2024 | Abandon | 30 | 9 | 0 | Yes | No |
| 17718116 | USE OF CATION-EXCHANGE CHROMATOGRAPHY IN THE FLOW-THROUGH MODE TO ENRICH POST-TRANSLATIONAL MODIFICATIONS | April 2022 | February 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17577684 | PROCOAGULANT COMPOUNDS | January 2022 | November 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17563665 | System and Method for Improved Transient Protein Expression in CHO Cells | December 2021 | January 2025 | Abandon | 36 | 3 | 0 | No | No |
| 17548410 | HYBRID SUGAR TRANSPORTERS WITH ALTERED SUGAR TRANSPORT ACTIVITY AND USES THEREOF | December 2021 | May 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17548124 | RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME | December 2021 | September 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17546001 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | December 2021 | March 2026 | Allow | 51 | 6 | 1 | Yes | No |
| 17613902 | COMPOSITION COMPRISING BIOFILM FORMING BACILLUS | November 2021 | July 2025 | Allow | 44 | 1 | 1 | No | No |
| 17607667 | NOVEL FAECALIBACTERIUM PRAUSNITZII STRAIN EB-FPDK11 AND USE THEREOF | October 2021 | August 2025 | Allow | 46 | 5 | 0 | No | No |
| 17513483 | APPLICATION OF UTX GENE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING LIPID DISEASES | October 2021 | June 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17605124 | METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV2.5 VECTOR | October 2021 | September 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17603936 | PRODUCTION OF SALIPRO PARTICLES | October 2021 | June 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17496092 | CHIMERIC CLOTTING FACTORS | October 2021 | November 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17449173 | IMPLANTABLE BIOSENSOR AND METHODS OF USE THEREOF | September 2021 | October 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17459169 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | August 2021 | December 2021 | Allow | 3 | 1 | 0 | No | No |
| 17429104 | ENZYMATIC PRODUCTION OF MANNOSE | August 2021 | February 2025 | Allow | 42 | 2 | 0 | No | No |
| 17396028 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | August 2021 | June 2023 | Allow | 23 | 1 | 0 | No | No |
| 17425095 | BETA-ARRESTIN MUTANTS | July 2021 | September 2025 | Allow | 50 | 3 | 1 | Yes | No |
| 17420585 | METHOD OF QUANTIFYING TARGET SUBSTANCE BY USING GLUCOSE METER AND CELL-FREE PROTEIN SYNTHESIS | July 2021 | November 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17420378 | ENGINEERED TRANSAMINASE POLYPEPTIDES | July 2021 | August 2025 | Allow | 50 | 3 | 1 | Yes | No |
| 17414245 | A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONS | June 2021 | December 2025 | Allow | 54 | 4 | 0 | Yes | No |
| 17347285 | GENETICALLY ENCODED RATIOMETRIC FLUORESCENT BARCODES | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17311137 | PRODUCTION METHOD FOR GENOME-EDITED CELLS | June 2021 | November 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17335357 | PRODUCTION OF SOLUBLE RELAXIN AND RELAXIN ANALOGS | June 2021 | January 2024 | Abandon | 32 | 4 | 1 | No | No |
| 17318740 | DEVICE AND METHOD FOR PREPARING AND ADMINISTERING ONE-COMPONENT FIBRIN SEALANT | May 2021 | January 2024 | Allow | 32 | 2 | 0 | No | No |
| 17314057 | RECOMBINANT PROTEINS COMPRISING BOTULINUM TOXIN AND CELL PENETRATING PEPTIDE AND COSMETIC COMPOSITION COMPRISING THEREOF | May 2021 | February 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17244738 | Variants of CPF1 (CAS12a) With Altered PAM Specificity | April 2021 | June 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17288619 | COMPOSITIONS AND METHODS FOR BIODEGRADING ALCOHOL | April 2021 | October 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17232942 | METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS | April 2021 | March 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17231769 | Stabilised Compositions of Factor VII Polypeptides | April 2021 | September 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17228130 | HUMAN COAGULATION FACTOR VII POLYPEPTIDES | April 2021 | September 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17212895 | METHODS AND COMPOSITIONS FOR PREPARING SURFACTANT PROTEIN D (SP-D) | March 2021 | August 2024 | Abandon | 40 | 2 | 0 | No | No |
| 17208736 | THROMBOLYTIC MICROSPHERES TO DISSOLVE VASO-OCCLUSIVE CLOTS | March 2021 | January 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17195615 | METHODS AND DEVICES FOR DETECTION OF COAGULATION IMPAIRMENT | March 2021 | November 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17190994 | METHODS AND COMPOSITIONS FOR REGULATION OF TRANSGENE EXPRESSION | March 2021 | August 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17272803 | METHODS FOR IMPROVING YIELDS OF L-GLUFOSINATE | March 2021 | October 2025 | Allow | 56 | 4 | 1 | Yes | Yes |
| 17269926 | MICROSAMPLING DETECTION IN DIABETES | February 2021 | May 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17173289 | SILK FIBROIN-BASED MICRONEEDLES AND METHODS OF MAKING THE SAME | February 2021 | September 2024 | Allow | 43 | 2 | 0 | Yes | Yes |
| 17160814 | METHOD FOR SEPARATING TARGET MOLECULES OR PARTICLES FROM FIBRINOGEN-CONTAINING SAMPLES INCLUDING BLOOD COMPONENTS | January 2021 | September 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17155935 | PURIFICATION OF CHIMERIC FVIII MOLECULES | January 2021 | October 2025 | Allow | 57 | 6 | 0 | Yes | Yes |
| 17255827 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | December 2020 | May 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17130812 | DELIVERY OF NEGATIVELY CHARGED PROTEINS USING CATIONIC LIPIDS | December 2020 | May 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17116817 | Enzyme Variants With Improved Ester Synthase Properties | December 2020 | June 2024 | Abandon | 42 | 2 | 0 | No | No |
| 15734682 | Promoter for Yeast | December 2020 | August 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 17108536 | MUTANT LYSENIN PORES | December 2020 | August 2023 | Allow | 32 | 1 | 1 | No | No |
| 17100806 | Compositions and Methods for Topical and Diagnostic and Therapeutic Transport | November 2020 | July 2023 | Abandon | 31 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TSAY, MARSHA M.
With a 19.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner TSAY, MARSHA M works in Art Unit 1656 and has examined 925 patent applications in our dataset. With an allowance rate of 46.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner TSAY, MARSHA M's allowance rate of 46.6% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TSAY, MARSHA M receive 2.78 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by TSAY, MARSHA M is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +48.2% benefit to allowance rate for applications examined by TSAY, MARSHA M. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 15.5% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 30.1% of cases where such amendments are filed. This entry rate is in the 43% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 71.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 73.2% of appeals filed. This is in the 62% percentile among all examiners. Of these withdrawals, 70.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 58.5% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.4% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.